Hypoxia-activated paclitaxel prodrugs enable PD-L1 degradation to potentiate cancer chemo-immunotherapy
Abstract The combination of chemotherapy and immune checkpoint blockade therapy shows great potential in tumor treatment, but their integration remains a great challenge. Herein, hypoxia-responsive prodrugs integrating paclitaxel (PTX) and bromodomain-containing protein 4 inhibitor JQ1 were designed...
Guardado en:
| Autores principales: | , , , , , , , , |
|---|---|
| Formato: | Artigo |
| Lenguaje: | Inglês |
| Publicado: |
BMC
2025-12-01
|
| Colección: | Journal of Nanobiotechnology |
| Materias: | |
| Acceso en línea: | https://doi.org/10.1186/s12951-025-03894-x |
| Etiquetas: |
Sin Etiquetas, Sea el primero en etiquetar este registro!
|